首页> 外文期刊>Advances in cancer research. >Managing Tumor Angiogenesis: Lessons from VEGF-Resistant Tumors and Wounds
【24h】

Managing Tumor Angiogenesis: Lessons from VEGF-Resistant Tumors and Wounds

机译:处理肿瘤血管生成:VEGF耐药肿瘤和伤口的教训

获取原文
获取原文并翻译 | 示例
           

摘要

It is now well established both experimentally and clinically, that new blood vessel growth is required for tumors to grow beyond a few millimeters and metastasize [Folkman, J. (1995). In: Mendelsohn, L., Howley, P., Israel, A. (Eds.), The Molecular Basis of Cancer, WB Saunders Company, Philadelphia, pp. 206-225]. Angiogenesis, the process of forming new blood vessels from preexisting vessels, provides the tumor with additional oxygen and nutrients for its continued growth. In addition, the proximity and increase in vascular density enhance the likelihood of tumor cells entering the bloodstream to eventually metastasize. Since the initial observations of Dr. Folkman in the late 1970s, research over the past 30 years has focused intensely on identifying points in which the angiogenic cycle can be disrupted and has become an important component of current therapies to limit tumor progression.
机译:现在在实验和临床上都已经确立,肿瘤生长超过几毫米并转移需要新的血管生长[Folkman,J。(1995)。在:Mendelsohn,L.,Howley,P.,以色列,A。(编辑),癌症的分子基础,WB Saunders Company,费城,第206-225页]。血管生成是从先前存在的血管中形成新血管的过程,为肿瘤提供了继续生长所需的额外氧气和营养。另外,血管密度的接近和增加增加了肿瘤细胞进入血流最终转移的可能性。自1970年代末Folkman博士的初步观察以来,过去30年的研究一直集中在确定可以破坏血管生成周期的点上,并已成为限制肿瘤进展的当前疗法的重要组成部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号